Staubach P, et al. - Omalizumab's impact on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1-antihistamines, was determined in the X-ACT study, a phase III, double-blind, placebo-controlled study. Angioedema-related QoL, skin-related QoL impairment, and psychological well-being were assessed following treatment with omalizumab 300 mg or placebo every 4 weeks for 28 weeks in CSU patients (18-75 years) with ≥4 angioedema episodes during the 6 months before inclusion. With omalizumab vs placebo, significant QoL improvements continuing until Week 28 were noted, which returned to placebo levels at the follow-up visit. Omalizumab vs placebo was also associated with decreased fear of suffocation due to angioedema. Overall, omalizumab treatment was supported in patients with severe H1-antihistamine-refractory CSU with angioedema.